Immuneering Announces Pricing of Upsized Initial Public Offering
July 29, 2021 22:48 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Appoints Michael Bookman as General Counsel and Secretary
July 20, 2021 06:47 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...
Immuneering Expands Board of Directors with Appointment of Ann E. Berman
July 14, 2021 06:47 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...
Immuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie Keating
April 27, 2021 10:17 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”) today announced the addition of Laurie Keating to its board of directors. Ms. Keating brings more than 25...
Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer
April 06, 2021 10:17 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from...
Immuneering Expands Leadership Team with Appointment of Carolina Garcia Rizo, Ph.D., MBA, as Chief Business Officer
March 25, 2021 10:17 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced Carolina Garcia Rizo, Ph.D., MBA, has joined the company as chief business officer. Dr. Rizo brings to...
Immuneering Completes Oversubscribed $62 Million Series B Financing
January 05, 2021 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the completion of an oversubscribed $62 million Series B financing led by Cormorant Asset Management, with...
Immuneering to Present at Oppenheimer's Private Life Sciences Company Call Series
August 11, 2020 10:17 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place...
Immuneering to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium
July 28, 2020 10:17 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the company’s participation in the LifeSci Partners Private Company Virtual Summer Symposium, taking place...
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
June 25, 2020 10:17 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a...